MedTrace Logo

Clinical Evaluation of an Atopic Skin Product Containing Picea Abies Resin Extract

NCT07573592 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2026-05-07

No results posted yet for this study

Summary

This study evaluates the repairing efficacy of a cosmetic cream containing Picea abies extract compared to a placebo (cream without extract) and a benchmark product. The trial involves 60 healthy subjects (aged 18-60) with atopy-prone and sensitive skin.

Over a 21-day period, the primary objective is to measure improvements in skin barrier function via transepidermal water loss (TEWL) and skin moisturization. A dermatologist will also assess soothing effects by evaluating skin dryness, redness, and itching sensations. Secondary objectives include measuring skin inflammation markers (TNFα, TSLP, and TARC) and subject-perceived efficacy through self-assessment questionnaires.

Conditions

  • Atopy
  • Skin Barrier to Water Loss

Interventions

OTHER

Atopic cream with Picea abies resin extract

Cosmetic cream containing Picea abies extract. Applied twice daily on clean and dry skin of the face and body for 21 days.

OTHER

Placebo

Base cosmetic formulation identical to the test product but without the active Picea abies resin extract. Applied twice daily on clean and dry skin of the face and body for 21 days.

OTHER

Aqualan-L Cream

Commercially available emollient cream (Aqualan-L) used as an active comparator. Applied twice daily on clean and dry skin of the face and body for 21 days.

Sponsors & Collaborators

  • Complife Italia Srl

    collaborator INDUSTRY

  • Business Finland

    collaborator OTHER

  • Repolar Pharmaceuticals Oy

    lead INDUSTRY

Principal Investigators

  • Maryam Ghanbarirad, Ph.D. · Repolar Pharmaceuticals Oy

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2026-03-18
Completion
2026-03-18

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07573592 on ClinicalTrials.gov